30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

ConMed Reports 2016 Revenue -

ConMed posted 2016 arthroscopy/soft tissue repair revenue of US $370.5MM, -4.7% vs. 2015 (U.S. -5.4%, ex-U.S. -4.3%), with 4Q16 revenue of $98.0MM, -5.9% vs. 4Q15. (U.S. -12.6%, ex-U.S. -1.1%)

  • U.S. 4Q revenue impacted by double-digit decline in capital sales and ongoing challenges in disposable arthroscopy products
  • Full-year ex-U.S. activity saw declines in capital sales in direct and export markets, and continued improvement in single-use product sales
  • Expecting revenue growth turnaround in 2H17, supported by Edge
  • Global release of Edge Bi-Polar Arthroscopic RF System continues; remaining markets pending regulatory clearance for 2017 launch include Korea (expected in 1Q) and Taiwan (4Q)
  • Most 2017 new product launches will come from orthopaedics business
  • Entered distribution agreement with Bovie Medical for its PlazXact Ablator, which will be marketed as the UltrAblator Bipolar series effective in March 2017; the inclusion of Bovie probes helps address a broader customer range


Sources: ConMed Corporation; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.